Interrelationships with Metabolic Syndrome, Obesity and Cardiovascular Risk

Area of Science:

• Cardiology and Metabolic Health
• Public Health and Epidemiology

Background:

• Cardiovascular (CV) disease is a leading cause of global morbidity and mortality.
• Metabolic syndrome (MetS) exacerbates CV disease risk, with recent reclassifications impacting diagnosis and treatment.
• CV disease risk is amplified by non-cardiac conditions interacting with MetS components.

Purpose of the Study:

• To highlight the complex interplay between cardiac and non-cardiac factors in MetS.
• To emphasize the need for integrated approaches in managing MetS and preventing CV events.
• To underscore the economic burden of MetS on healthcare systems.

Main Methods:

• Review of current classifications and treatment strategies for MetS.
• Analysis of the synergistic and independent relationships between MetS components and non-cardiac comorbidities.
• Examination of the impact of these combined factors on CV outcomes.

Main Results:

• MetS components include hypertension, diabetes mellitus (DM), and dyslipidemia (DLD).
• Non-cardiac factors like liver disease, renal disease, obesity, polycystic ovarian syndrome, and obstructive sleep apnea (OSA) significantly worsen CV risk.
• The combined effect of these factors potentiates adverse CV events and increases healthcare costs.

Conclusions:

• Early diagnosis and management of OSA and severe obesity are critical for CV disease prevention.
• Comprehensive management strategies addressing both cardiac and non-cardiac factors are essential for mitigating MetS-related CV risks.
• Targeted interventions beyond traditional MetS components are needed for effective primary and secondary CV disease prevention.